These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 18260867)
21. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352 [TBL] [Abstract][Full Text] [Related]
22. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E; Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780 [TBL] [Abstract][Full Text] [Related]
23. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls. Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376 [TBL] [Abstract][Full Text] [Related]
24. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial. Derhaschnig U; Pachinger C; Jilma B Am Heart J; 2004 Apr; 147(4):E17. PubMed ID: 15077100 [TBL] [Abstract][Full Text] [Related]
25. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Ronner E; Boersma E; Akkerhuis KM; Harrington RA; Lincoff AM; Deckers JW; Karsch K; Kleiman NS; Vahanian A; Topol EJ; Califf RM; Simoons ML Eur Heart J; 2002 Feb; 23(3):239-46. PubMed ID: 11792139 [TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Hobbach HP; Schuster P Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467 [TBL] [Abstract][Full Text] [Related]
27. Antiplatelet intervention in acute coronary syndrome. Arora RR; Rai F Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648 [TBL] [Abstract][Full Text] [Related]
28. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years? Silva MA; Gandhi PJ J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937 [TBL] [Abstract][Full Text] [Related]
29. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Gibson CM; Kirtane AJ; Murphy SA; Rohrbeck S; Menon V; Lins J; Kazziha S; Rokos I; Shammas NW; Palabrica TM; Fish P; McCabe CH; Braunwald E; Am Heart J; 2006 Oct; 152(4):668-75. PubMed ID: 16996831 [TBL] [Abstract][Full Text] [Related]
30. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related]
31. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE; Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469 [TBL] [Abstract][Full Text] [Related]
32. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. Bagai A; White JA; Lokhnygina Y; Giugliano RP; Van de Werf F; Montalescot G; Armstrong PW; Tricoci P; Gibson CM; Califf RM; Harrington RA; Newby LK Am Heart J; 2013 Sep; 166(3):466-73. PubMed ID: 24016495 [TBL] [Abstract][Full Text] [Related]
33. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. Fitchett DH; Langer A; Armstrong PW; Tan M; Mendelsohn A; Goodman SG; Am Heart J; 2006 Feb; 151(2):373-9. PubMed ID: 16442903 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of pre-hospital use of glycoprotein IIb/IIIa inhibitors in ST-segment elevation myocardial infarction before mechanical reperfusion in a rapid-transfer network (from the Acute Myocardial Infarction Registry of Brittany). Auffret V; Oger E; Leurent G; Filippi E; Coudert I; Hacot JP; Castellant P; Rialan A; Delaunay R; Rouault G; Druelles P; Boulanger B; Treuil J; Avez B; Bedossa M; Boulmier D; Le Guellec M; Le Breton H Am J Cardiol; 2014 Jul; 114(2):214-23. PubMed ID: 24878117 [TBL] [Abstract][Full Text] [Related]
35. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation. Lev EI; Hasdai D; Scapa E; Tobar A; Assali A; Lahav J; Battler A; Badimon JJ; Kornowski R J Am Coll Cardiol; 2004 Mar; 43(6):966-71. PubMed ID: 15028351 [TBL] [Abstract][Full Text] [Related]
36. A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. Roe MT; Christenson RH; Ohman EM; Bahr R; Fesmire FM; Storrow A; Mollod M; Peacock WF; Rosenblatt JA; Yang H; Fraulo ES; Hoekstra JW; Gibler WB; ; Am Heart J; 2003 Dec; 146(6):993-8. PubMed ID: 14660990 [TBL] [Abstract][Full Text] [Related]
37. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. Fischell TA; Attia T; Rane S; Salman W J Invasive Cardiol; 2006 Oct; 18(10):487-91. PubMed ID: 17042093 [TBL] [Abstract][Full Text] [Related]
38. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466 [TBL] [Abstract][Full Text] [Related]
39. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
40. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors. De Carlo M; Maselli D; Cortese B; Ciabatti N; Gistri R; Levantino M; Balbarini A; De Caterina R; Petronio AS Int J Cardiol; 2008 Jan; 123(3):229-33. PubMed ID: 17433463 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]